Global News and Digital Insights
for the Healthcare Industry

FDA approves Alembic Pharmaceuticals’ bronchoconstriction drug

Alembic Pharmaceuticals bags approval from the USFDA for its Arformoterol Tartrate Inhalation Solution which is the equivalent of Sunovion Pharmaceuticals’ reference listed drug product (RlD), Brovana Inhalation Solution. Alembic Pharmaceuticals, in partnership with Orbicular Pharmaceutical Technologies, codeveloped Arformoterol Tartrate Inhalation Solution, which has been approved by USFDA for its Abbreviated New Drug Application (ANDA). The said drug will be used to treat chronic obtrusive pulmonary disease (COPD), bronchitis, and emphysema. Alembic Pharmaceuticals has a total of 167 ANDA approvals including this second nod for its Arformoterol Tartrate Inhalation Solution.

Read More from Business Standard